Interventions in progressive supranuclear palsy

被引：12

作者：

Koros, Christos ^{[1
]}

Stamelou, Maria ^{[1
,2
,3
]}

机构：

[1] Univ Athens, Dept Neurol 2, Attikon Hosp, Movement Disorders Clin, Athens, Greece

[2] Hygeia Hosp, Dept Movement Disorders, Athens, Greece

[3] Univ Marburg, Neurol Clin, Marburg, Germany

来源：

PARKINSONISM & RELATED DISORDERS | 2016年 / 22卷

关键词：

Progressive supranuclear palsy; Richardson's syndrome; Treatment; Glycogen synthase kinase-3 inhibitors; Tideglusib; Davunetide; Immunization; GLYCOGEN-SYNTHASE KINASE-3-BETA; GSK-3 INHIBITOR TIDEGLUSIB; TAU; TRANSMISSION; TAUOPATHY; PATHOLOGY; FUTURE;

D O I：

10.1016/j.parkreldis.2015.09.033

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Progressive supranuclear palsy (PSP) an atypical parkinsonian with a common phenotype comprising early falls, the characteristic slowing of vertical saccades and a frontal syndrome with marked apathy (Richardson's syndrome). Currently, no effective symptomatic or neuroprotective treatment is available for PSP. Current medical have a limited role in PSP. Novel experimental treatments include davunetide or tideglusib, both inhibitors of glycogen synthase kinase-3 (GSK-3) that failed to improve the clinical outcome of PSP patients in two recent studies. Future interventions aiming at tau dysfunction and passive or active immunization are ongoing or underway. (C) 2015 Elsevier Ltd. All rights reserved.

引用

页码：S93 / S95

页数：3

共 30 条

[1]

Apetauerova D, 2014, MOVEMENT DISORD, V29, pS102

[2] Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial [J].

Boxer, Adam L. ;

Lang, Anthony E. ;

Grossman, Murray ;

Knopman, David S. ;

Miller, Bruce L. ;

Schneider, Lon S. ;

Doody, Rachelle S. ;

Lees, Andrew ;

Golbe, Lawrence I. ;

Williams, David R. ;

Corvol, Jean-Cristophe ;

Ludolph, Albert ;

Burn, David ;

Lorenzl, Stefan ;

Litvan, Irene ;

Roberson, Erik D. ;

Hoeglinger, Guenter U. ;

Koestler, Mary ;

Jack, Clifford R., Jr. ;

Van Deerlin, Viviana ;

Randolph, Christopher ;

Lobach, Iryna V. ;

Heuer, Hilary W. ;

Gozes, Illana ;

Parker, Lesley ;

Whitaker, Steve ;

Hirman, Joe ;

Stewart, Alistair J. ;

Gold, Michael ;

Morimoto, Bruce H. .

LANCET NEUROLOGY, 2014, 13 (07) :676-685

[3] Brain homogenates from human tauopathies induce tau inclusions in mouse brain [J].

Clavaguera, Florence ;

Akatsu, Hiroyasu ;

Fraser, Graham ;

Crowther, R. Anthony ;

Frank, Stephan ;

Hench, Juergen ;

Probst, Alphonse ;

Winkler, David T. ;

Reichwald, Julia ;

Staufenbiel, Matthias ;

Ghetti, Bernardino ;

Goedert, Michel ;

Tolnay, Markus .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (23) :9535-9540

[4] Transmission and spreading of tauopathy in transgenic mouse brain [J].

Clavaguera, Florence ;

Bolmont, Tristan ;

Crowther, R. Anthony ;

Abramowski, Dorothee ;

Frank, Stephan ;

Probst, Alphonse ;

Fraser, Graham ;

Stalder, Anna K. ;

Beibel, Martin ;

Staufenbiel, Matthias ;

Jucker, Mathias ;

Goedert, Michel ;

Tolnay, Markus .

NATURE CELL BIOLOGY, 2009, 11 (07) :909-U325

[5] Zolpidem in progressive supranuclear palsy [J].

Daniele, A ;

Moro, E ;

Bentivoglio, AR .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (07) :543-544

[6] Zolpidem in Progressive Supranuclear Palsy [J].

Dash, Sandip K. .

CASE REPORTS IN NEUROLOGICAL MEDICINE, 2013, 2013

[7] Treatment of Alzheimer's Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study [J].

del Ser, Teodoro ;

Steinwachs, Klaus C. ;

Gertz, Hermann J. ;

Andres, Maria V. ;

Gomez-Carrillo, Belen ;

Medina, Miguel ;

Vericat, Joan A. ;

Redondo, Pilar ;

Fleet, David ;

Leon, Teresa .

JOURNAL OF ALZHEIMERS DISEASE, 2013, 33 (01) :205-215

[8]

Ferrer I., 2005, Current Alzheimer Research, V2, P3, DOI 10.2174/1567205052772713

[9] Tau gene mutations and their effects [J].

Goedert, M .

MOVEMENT DISORDERS, 2005, 20 :S45-S52

[10] Tau Pathology and Future Therapeutics [J].

Gozes, I. .

CURRENT ALZHEIMER RESEARCH, 2010, 7 (08) :685-696

← 1 2 3 →